头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对耐美罗培南铜绿假单胞菌分离株的体外活性评估。
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
作者信息
Buehrle Deanna J, Shields Ryan K, Chen Liang, Hao Binghua, Press Ellen G, Alkrouk Ammar, Potoski Brian A, Kreiswirth Barry N, Clancy Cornelius J, Nguyen M Hong
机构信息
Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA XDR Pathogen Laboratory, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
出版信息
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
Abstract
We compared ceftazidime-avibactam, ceftolozane-tazobactam, ceftazidime, cefepime, and piperacillin-tazobactam MICs for 38 meropenem-resistant Pseudomonas aeruginosa isolates. No isolates harbored carbapenemases; 74% were oprD mutants. Ceftazidime-avibactam and ceftolozane-tazobactam were active against 92% of the isolates, including 80% that were resistant to all three β-lactams. Forty-three percent of ceftazidime-avibactam-susceptible isolates and 6% of ceftolozane-tazobactam-susceptible isolates exhibited MICs at the respective breakpoints. Ceftolozane-tazobactam and ceftazidime-avibactam are therapeutic options for meropenem-resistant P. aeruginosa infections that should be used judiciously to preserve activity.
摘要
我们比较了头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、头孢他啶、头孢吡肟和哌拉西林-他唑巴坦对38株耐美罗培南铜绿假单胞菌分离株的最低抑菌浓度（MIC）。所有分离株均未携带碳青霉烯酶；74%为oprD突变体。头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对92%的分离株有活性，其中包括80%对所有三种β-内酰胺类耐药的分离株。头孢他啶-阿维巴坦敏感分离株中有43%以及头孢洛扎-他唑巴坦敏感分离株中有6%的MIC分别处于各自的折点。头孢洛扎-他唑巴坦和头孢他啶-阿维巴坦是耐美罗培南铜绿假单胞菌感染的治疗选择，应谨慎使用以保留其活性。
相似文献
1
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3227-31. doi: 10.1128/AAC.02969-15. Print 2016 May.
2
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01858-17. Print 2017 Dec.
3
Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Int J Infect Dis. 2017 Sep;62:39-43. doi: 10.1016/j.ijid.2017.06.007. Epub 2017 Jun 10.
4
In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
J Glob Antimicrob Resist. 2020 Mar;20:334-338. doi: 10.1016/j.jgar.2019.09.016. Epub 2019 Sep 27.
5
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
6
Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01350-17. Print 2017 Dec.
7
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2533-2541. doi: 10.1007/s10096-021-04308-0. Epub 2021 Jul 22.
8
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
Int J Antimicrob Agents. 2019 Jun;53(6):774-780. doi: 10.1016/j.ijantimicag.2019.02.022. Epub 2019 Mar 2.
9
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.
J Antimicrob Chemother. 2019 Dec 1;74(12):3497-3504. doi: 10.1093/jac/dkz379.
10
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.
引用本文的文献
1
[In vitro activity of ceftazidime- avibactam and ceftolozane- tazobactam against clinical isolates of enterobacteriaceae and : results from a trauma center and burn unit in tunisia].
Ann Burns Fire Disasters. 2025 Mar 31;38(1):31-37. eCollection 2025 Mar.
2
Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.
Antimicrob Resist Infect Control. 2025 Feb 11;14(1):10. doi: 10.1186/s13756-025-01518-5.
3
Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.
Antibiotics (Basel). 2023 Dec 5;12(12):1700. doi: 10.3390/antibiotics12121700.
4
Nosocomial pneumonia: Current etiology and impact on antimicrobial therapy.
Rev Esp Quimioter. 2023 Nov;36 Suppl 1(Suppl 1):9-14. doi: 10.37201/req/s01.03.2023. Epub 2023 Nov 24.
5
In Vitro Activity of New β-Lactamase Inhibitor Combinations against , , and ESBL-Producing Enterobacteriales Uropathogens.
Antibiotics (Basel). 2023 Sep 25;12(10):1481. doi: 10.3390/antibiotics12101481.
6
Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of .
Pharmaceuticals (Basel). 2023 Aug 30;16(9):1230. doi: 10.3390/ph16091230.
7
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0040523. doi: 10.1128/aac.00405-23. Epub 2023 Jul 5.
8
Infections in Cancer Patients.
Pathogens. 2022 Jun 12;11(6):679. doi: 10.3390/pathogens11060679.
9
New Drugs for the Treatment of Infections with Limited Treatment Options: A Narrative Review.
Antibiotics (Basel). 2022 Apr 26;11(5):579. doi: 10.3390/antibiotics11050579.
10
Ceftolozane-tazobactam in nosocomial pneumonia.
Rev Esp Quimioter. 2022 Apr;35 Suppl 1(Suppl 1):35-39. doi: 10.37201/req/s01.08.2022. Epub 2022 Apr 22.
本文引用的文献
1
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Int J Antimicrob Agents. 2015 Nov;46(5):502-10. doi: 10.1016/j.ijantimicag.2015.07.004. Epub 2015 Aug 10.
2
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Clin Ther. 2015 Jul 1;37(7):1564-71. doi: 10.1016/j.clinthera.2015.05.501. Epub 2015 Jun 15.
3
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.
4
Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.
Antimicrob Agents Chemother. 2015 Mar;59(3):1797-801. doi: 10.1128/AAC.03894-14. Epub 2014 Dec 22.
5
Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2015 Feb;59(2):1020-9. doi: 10.1128/AAC.04238-14. Epub 2014 Dec 1.
6
Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35.
Antimicrob Agents Chemother. 2014 Dec;58(12):7358-66. doi: 10.1128/AAC.03930-14. Epub 2014 Sep 29.
7
In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
Antimicrob Agents Chemother. 2014 Nov;58(11):6913-9. doi: 10.1128/AAC.03267-14. Epub 2014 Sep 15.
8
Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Antimicrob Agents Chemother. 2014 Nov;58(11):6844-50. doi: 10.1128/AAC.03681-14. Epub 2014 Sep 2.
9
Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.
Antimicrob Agents Chemother. 2014 Oct;58(10):5704-13. doi: 10.1128/AAC.03057-14. Epub 2014 Jul 14.
10
Molecular mechanisms of β-lactam resistance in carbapenemase-producing Klebsiella pneumoniae from Sri Lanka.
J Med Microbiol. 2014 Aug;63(Pt 8):1087-1092. doi: 10.1099/jmm.0.076760-0. Epub 2014 May 22.
Zotero 插件